DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

Appeal No. 7083 of 2026 filed by Sunil Kumar

SEBI 1 hr ago·9 Oct 2026, 12:32 pm

Company SEBI

The Securities Appellate Tribunal (SAT) has admitted an appeal filed by Sunil Kumar, marking a significant legal development for the affected company. This appeal challenges a recent order passed by the Securities and Exchange Board of India (SEBI), which imposed certain regulatory penalties or directions on the firm. The admission of the appeal signals that the tribunal will now review the SEBI's decision to determine if it was legally sound and justified.

This legal battle is important for investors as it introduces uncertainty regarding the company's regulatory standing and potential financial liabilities. The outcome could influence the stock's performance, depending on whether the tribunal upholds or overturns SEBI's order. Investors should monitor the tribunal's proceedings and the company's official statements for clarity on the potential impact of this regulatory scrutiny.